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Abstract
Increasing evidence demonstrates that ubiquitin specific protease 39 (USP39) plays an oncogenic role in various human
tumors. Here, using expression analysis of the publicly available Oncomine database, clinical glioma patient samples, and
glioma cells, we found that USP39 was overexpressed in human gliomas. Knockdown of USP39 in glioma cells
demonstrated that the protein promoted cell growth, invasion and migration in vitro and in a tumor model in nude mice. To
identify mediators of USP39 growth-promoting properties, we used luciferase reporter constructs under transcriptional
control of various promoters specific to seven canonical cancer-associated pathways. Luciferase activity from a synthetic
TEAD-dependent YAP/TAZ-responsive reporter, as a direct readout of the Hippo signaling pathway, was decreased by 92%
in cells with USP39 knockdown, whereas the luciferase activities from the other six cancer pathways, including MAPK/
ERK, MAPK/JNK, NFκB, Notch, TGFβ, and Wnt, remained unchanged. TAZ protein expression however was decreased
independent of canonical Hippo signaling. Immunohistochemistry revealed a positive correlation between USP39 and TAZ
proteins in orthotopic xenografts derived from modified glioma cells expressing USP39 shRNAs and primary human glioma
samples (p < 0.05). Finally, loss of USP39 decreased TAZ pre-mRNA splicing efficiency in glioma cells in vitro, which led
to reduced levels of TAZ protein. In summary, USP39 has oncogenic properties that increase TAZ protein levels by inducing
maturation of its mRNA. USP39 therefore provides a novel therapeutic target for the treatment of human glioma.
Introduction
Malignant gliomas are the most common aggressive and
fatal primary brain tumors in adults [1, 2]. Despite great
advances in treatment, median survival for patients with
glioblastoma (GBM), the most aggressive glioma, is
14.5–16.6 months [3]. The current standard of care is
largely ineffective due to complex features, which
include aggressive growth and diffuse invasion. In recent
years, much of the research effort has focused on the
molecular basis of the disease with the goal of translating
this better understanding into viable therapies [4].
Ubiquitin specific protease 39 (USP39) is a member of
a family of deubiquitinating proteins that are classified
based on the sequence similarity in the Dub-domain.
However, USP39 is interestingly entirely deprived of
deubiquitinating activity due to the absence of conserved
active-site residues (a cysteine, histidine, and aspartic
acids) in the Dub-domain [5]. USP39 is also known as
Sad1p in yeast and a 65 kDa SR-related protein in
humans, both of which have been implicated in assembly
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of the mature spliceosome complex, suggesting a role in
mRNA splicing [6–8]. Previous studies have demon-
strated that USP39 is involved in splicing of the tran-
script for Aurora B [5]. Mutation of zebrafish USP39
induces mRNA splicing defects in the retinoblastoma
gene, rb1 [9]. USP39 is also reported to be a pivotal
regulator of EGFR pre-mRNA splicing [10]. In addition,
an oncogenic role for USP39 has been reported in many
malignant tumors, such as prostate cancer [10], oral
squamous cell carcinoma [11], gastric cancer [12], mel-
anoma [13], osteosarcoma [14], breast cancer [15],
hepatocellular carcinoma [16], medullary thyroid carci-
noma [17], lung cancer [18], pancreatic cancer [19],
colorectal cancer [20], and renal cell carcinoma [21].
However, the role of USP39 in glioma has not been well
defined.
TAZ, also known as WWTR1 (WW-domain contain-
ing transcriptional regulator 1), a transcriptional coacti-
vator with a PDZ-binding motif, and its paralog, yes-
associated protein (YAP), are associated primarily with
activity in the Hippo tumor suppressor pathway, which
plays a prominent role in cell proliferation, cell apop-
tosis, tumor metastasis, and maintenance of stem cell
traits in cancer [22–25]. Classic Hippo signaling is
transmitted through a kinase cascade. The upstream
kinases, MST1 and MST2, work together with the
adaptor protein SAV1/WW45 to phosphorylate and
activate LATS1 and LATS2. These activated LATS
kinases together with MOB1 then phosphorylate the
TAZ and YAP effector proteins [26]. Phosphorylated
TAZ is mainly localized in the cytoplasm, whereas
unphosphorylated TAZ enters the nucleus, where the
protein functions as a transcriptional coactivator to pro-
mote tumor growth through the induction of gene tran-
scription [27–29]. Elevated expression and activity of
TAZ have been identified in various human cancers, such
as melanoma, hepatocellular carcinoma, and breast,
liver, and colorectal cancers [24, 30–32]. In addition,
TAZ expression has been found to be increased, posi-
tively correlated with tumor grade, and involved in
regulating mesenchymal differentiation in glioma
[33, 34]. However, several aspects of the role of TAZ in
glioma remain unknown.
In this work, we investigate the expression of USP39 in
human gliomas and comprehensively study the functional
role of USP39 in the development of the disease using
model systems both in vitro and in vivo. We reveal that
USP39 has growth-promoting properties in human gliomas,
and investigation of putative oncogenic mechanisms illu-
minates a role in mRNA processing of TAZ, a transcrip-
tional regulator with known oncogenic properties. USP39
may thus be a potential prognostic biomarker and ther-
apeutic target in the treatment of glioma patients.
Results
Increased expression of USP39 is associated with
increasing tumor grade in primary human gliomas
We first analyzed USP39 expression in human cancer in the
publicly available database Oncomine. Results demon-
strated that USP39 was upregulated in many tumor types,
including brain and CNS cancer (Supplementary Fig. 1a).
We then analyzed USP39 mRNA expression specifically in
GBM, and found that the numbers of samples in TCGA and
Sun Brain datasets are greater (>100 samples) than in other
datasets. In these two datasets, USP39 was distinctly
upregulated in GBM compared with nonneoplastic brain
tissue samples (Supplementary Fig. 1b).
We validated these in silico results first through immu-
nohistochemical (IHC) staining of primary human glioma
samples. Staining for USP39 was increased in glioma
samples (Fig. 1a), and levels in high-grade gliomas (WHO
III–IV; n= 28) were increased compared with low-grade
gliomas (WHO II; n= 18) and nonneoplastic human brain
tissue samples (n= 6, Fig. 1b). These results indicated that
USP39 protein expression was correlated with higher tumor
grade. We verified that USP39 expression was associated
with tumor grade, independent from other clin-
icopathological factors, including age, gender, tumor size,
cystic change, and edema, which suggested that USP39
could be a potential diagnostic factor for glioma patients
(Table 1, p < 0.05). Western blotting analysis of primary
human glioma samples further supported these findings.
USP39 protein levels were increased in high-grade glioma
samples (WHO III–IV; n= 8) relative to low-grade glioma
(WHO II; n= 4) and nonneoplastic human brain tissue
samples (n= 3; Fig. 1c).
We also examined USP39 mRNA and protein levels in
several cell types in culture, including P3, LN18, U87MG,
U251, and A172 glioma cells, and normal human astrocytes
(NHA), using qRT-PCR and western blotting. USP39
mRNA and protein expression were significantly higher in
the glioma cell populations than in NHA (1.9–4.2×; Fig. 1d,
e). These data all together indicated that increased expres-
sion of USP39 is associated with increasing tumor grade in
gliomas and that the protein may be involved in glioma
progression.
USP39 promotes proliferation, invasion, and
migration of glioma cells in vitro
To examine the function of the protein in glioma develop-
ment, we knocked down expression of USP39 in glioma
cells in culture with short hairpin RNAs (shRNAs) in len-
tiviral constructs. Expression of USP39 was high in all
glioma cells tested relative to NHA (Fig. 1e), so we
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randomly chose U87MG, A172, and P3 glioma cells for
these experiments. ShRNAs targeting two different coding
regions of USP39 (sh-USP39-1 and sh-USP39-2) were
designed and tested in the three glioma cell populations.
Both efficiently knocked down USP39 mRNA by about
80% and protein expression by about 60% in all three
glioma cell populations (Fig. 2a, b). Cell growth was sig-
nificantly reduced in cells expressing the USP39 shRNAs as
assessed in three different assays, including Cell Counting
Kit-8 (CCK8), colony forming, and EdU assays (Fig. 2c–f
and Supplementary Fig. 2a), compared with negative con-
trols (NC). In cell invasion and migration assays, the
number of invaded and migrated cells was reduced by
nearly 50% in cells expressing the USP39 shRNAs (Fig. 2g
and Supplementary Fig. 2b). These findings indicated that
USP39 promoted proliferation, invasion, and migration of
glioma cells in vitro.
Downregulation of USP39 reduces cell growth
in vivo
To examine the effect of USP39 on cell growth in vivo, we
generated an orthotopic tumor model by implanting
U87MG- and P3-NC/-sh-USP39-1 cells in the brains of
nude mice. These cells were expressing luciferase, so that
signal emanating from tumors could be measured over time
at regular intervals. Bioluminescence signals did increase
overall in mice over the 20-day time period (Fig. 3a), but
USP39 knockdown led to a decreased rate in tumor growth.
Total flux was used as a measure to quantify the in vivo
bioluminescence imaging results. Total flux in U87MG-sh-
USP39-1 tumors was markedly different at 10 days after
injection of cells compared with U87MG-NC control
tumors. Total flux was decreased by 45% at this time point.
Table 1 Association between USP39 expression and
clinicopathological factors in human glioma





<60 32 10 22 0.4469
≥60 14 6 8
Gender
Male 29 9 20 0.4857
Female 17 7 10
Tumor size (cm)
<4 25 10 15 0.4176
≥4 21 6 15
Cystic change
Absent 18 7 11 0.6392
Present 28 9 19
Edema
None to mild 35 11 24 0.3942
Moderate to severe 11 5 6
WHO grade
Low grade (WHO II) 18 10 8 0.0177
High grade (WHO III–IV) 28 6 22
Fig. 1 USP39 is overexpressed
in glioma patient samples and
glioma cells. a Representative
images of IHC staining in
human glioma and
nonneoplastic brain tissue
samples (n= 52). Scale bars,
50 µm. b Graphical
representation of IHC scores in
human glioma and
nonneoplastic brain tissue
samples. c Western blotting
analysis for USP39 levels in
lysates (20 µg) prepared from
human glioma and
nonneoplastic brain tissues (n=
15). d qRT-PCR and e western
blotting analysis for USP39
levels in NHA, LN18, P3,
U87MG, U251, and A172 cells.
GAPDH was used for
normalization. Student’s t-test:
**p < 0.01
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By 20 days, this difference had increased with values from
U87MG-sh-USP39-1 tumors being 75% less than controls
(Fig. 3b). The trend was the same for P3-sh-USP39-1 cells,
although the reduced tumor growth of 58% relative to
controls was not evident until 15 days after implantation
(Fig. 3b).
Histological examination revealed that U87MG- and P3-
sh-USP39-1 orthotopic xenografts tended to be less inva-
sive and more circumscribed than controls (Fig. 3c). Fur-
thermore, in Kaplan–Meier analysis of survival data from
tumor bearing mice, animals implanted with U87MG- and
P3-sh-USP39-1 cells exhibited better overall survival
(median survival: 27 days vs. 33 days, U87MG-NC and
U87MG-sh-USP39-1, respectively; 26 days vs. 31 days, P3-
NC and P3-sh-USP39-1, respectively; Fig. 3d). Together,
these findings demonstrated that USP39 depletion led to
decreased cell growth in vivo.
USP39 regulates TAZ independently of classical
Hippo signaling
To explore the potential mechanisms underlying USP39-
induced malignant behaviors in glioma, we transfected a
series of luciferase reporter constructs to assay signaling
activity from seven different pathways, such as Notch,
Hippo, and Wnt, which are typically dysregulated in
human cancers. In these constructs, luciferase is regulated
by a transcriptional element specific to each pathway. We
found that the luciferase activity from a synthetic TEAD-
dependent YAP/TAZ-responsive reporter, as a direct
Fig. 2 Knockdown of USP39 inhibits proliferation, invasion, and
migration of glioma cells in vitro. a qRT-PCR analysis for USP39
mRNA levels in U87MG, A172, and P3 cells infected with two dif-
ferent USP39 shRNAs, sh-USP39-1 and -2. b Western blotting ana-
lysis of USP39 protein levels in U87MG, A172, and P3 cells infected
with sh-USP39-1 and -2. c OD values from CCK8 assays of U87MG-,
A172-, and P3-sh-USP39-1 and -2 plotted over time in hours to
evaluate cell viability. d, e Representative images of colony forming
assays for U87MG-, A172-, and P3-sh-USP39-1 and -2 to evaluate cell
proliferation. Cells were fixed and stained with crystal violet. Colonies
were counted, and results are represented in the bar graph. f Graphic
representation of EdU-positive cells% in U87MG- and A172-NC, -sh-
USP39-1, and -sh-USP39-2 cells. g Graphic representation of invaded
and migrated cells counts from cell invasion and migration assays.
Student’s t-test: **p < 0.01, ***p < 0.001
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readout of Hippo activity, was decreased by 92% in
U87MG-sh-USP39-1 cells, whereas the luciferase activ-
ities of the other six cancer pathways, including MAPK/
ERK, MAPK/JNK, NFκB, Notch, TGFβ, and Wnt,
remained unchanged (Fig. 4a).
Western blotting analysis showed that TAZ protein
expression was also reduced in U87MG-, A172-, and P3-
sh-USP39-1 cells relative to controls, but other key
components of the Hippo pathway, including LATS1,
LATS2, and YAP, remained unchanged (Fig. 4b). In
view of the critical role of YAP/TAZ in activating
transcription and YAP protein remained unchanged in
our work, we validate the individual effect of TAZ using
luciferase assays (Supplementary Fig. 3a). We hypo-
thesized that USP39 might promote malignant behaviors
through TAZ. We performed IHC on sections from the
xenografts derived from the modified cell types to
determine the relationship between these proteins
in vivo. The IHC scores demonstrated that TAZ protein
expression was decreased after knockdown of USP39
Fig. 3 Knockdown of USP39 decreases proliferation, invasion, and
migration of glioma cells in vivo. a Representative images of luci-
ferase bioluminescence at the indicated days after injection of
luciferase-expressing U87MG and P3 cells into the brains of nude
mice. b Graphic representation of the total flux at the indicated days
for the indicated cell types. c Representative images of HE staining of
orthotopic xenografts derived from the indicated cell types, U87MG-
and P3-sh-USP39-1 cells and controls. Scale bars, 1000 and 200 µm. d
Kaplan–Meier analysis of survival for tumor bearing mice implanted
with U87MG- and P3-sh-USP39-1 cells and controls. Student’s t-test:
n.s.= not significant, *p < 0.05, **p < 0.01, ***p < 0.001. Log-rank
test: p < 0.01
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(Fig. 4c, d). In addition, in line with the results from Fig. 3,
IHC scores for Ki67, a marker for proliferation, were cor-
respondingly decreased (Fig. 4c, d). Finally, we performed
IHC on primary human glioma samples (n= 33) and found
that IHC scores for USP39 correlated with scores obtained
for TAZ (p < 0.05; Fig. 4e, f). Thus, USP39 and TAZ
proteins were positively correlated. All together, these
results demonstrated that loss of USP39 led to decreased
TAZ but not other components of the Hippo signaling
pathway including LATS1/2.
USP39 regulates TAZ protein expression through
TAZ mRNA maturation
USP39 has been reported to be involved in pre-mRNA splicing
of certain genes [6–8, 35]. We therefore investigated whether
Fig. 4 USP39 regulates TAZ through a LATS1/2-independent
mechanism. a Graphic representation of relative luciferase activity in
reporter assays to probe activation through seven cancer-associated
pathways in U87MG-sh-USP39-1 cells. Luciferase reporter constructs
regulated by pathway specific promoters were transfected into cells
and assayed for luciferase activity. b Western blotting analysis of TAZ
and other key components of the Hippo signaling pathway in U87MG-,
A172-, and P3-sh-USP39-1 cells relative to controls. GAPDH was
used for normalization. c Representative images of IHC staining of
USP39, TAZ, and Ki67 levels in xenograft sections from U87MG-NC,
U87MG-sh-USP39-1, P3-NC, and P3-sh-USP39-1 groups. Scale bars,
50 µm. d Graphic representation of IHC scores for USP39, TAZ, and
Ki67 levels from indicated groups. e Representative images of IHC
staining of USP39 and TAZ in primary human glioma samples (n=
33). Scale bars, 50 µm. f Correlation of USP39 and TAZ protein
expression in primary human glioma samples. IHC scores are indi-
cated in parentheses. Student’s t-test: *p < 0.05, **p < 0.01. χ2-test and
Fisher’s exact test: p < 0.05
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USP39 had a role in posttranscriptional regulation of TAZ
mRNA splicing. Little is currently known about mRNA spli-
cing of TAZ transcripts and their final form. However,
according to the Ensembl database, TAZ has three predicted
primary transcripts, which could yield a translated product
corresponding to the longest protein isoform of TAZ observed
in this work. Although these predicted primary transcripts have
different lengths, they share some common regions. For
example, in the longest primary transcript, the region from
introns 3–4 to introns 7–8 is also contained in two other pri-
mary transcripts. Because these exons (exons 4–7) are equally
represented in the different transcripts, the region from exons 4
to 5 in the longest primary transcript was selected to design
specific primers to distinguish TAZ spliced mRNA and TAZ
unspliced mRNA (Fig. 5a). Using qRT-PCR, we detected
increased levels of unspliced mRNA transcripts in U87MG-sh-
USP39-1 and A172-sh-USP39-1 cells relative to controls,
whereas spliced mRNA was significantly decreased (~70%;
Fig. 5b, c). Besides, we performed the RNA-binding protein
immunoprecipitation assay (RIP) on extracts prepared from
U87MG and A172 using USP39 antibody. The results of qRT-
PCR demonstrated that TAZ expression was significantly
enriched in USP39 pull downs compared with IgG controls
(Fig. 5d, e). These data suggested that knockdown of USP39
led to decreased TAZ protein levels at least in part by sup-
pressing splicing of its pre-mRNA.
Downregulation of USP39 decreases TAZ
transcriptional activity
To better clarify the regulation of TAZ by USP39, cel-
lular localization of the TAZ protein was examined.
Fig. 5 Knockdown of USP39 decreases TAZ protein levels by redu-
cing the splicing of TAZ pre-mRNA. a Schematic model (top) repre-
senting the region common among the three longest primary
transcripts of TAZ predicted from the Ensembl database. Graphic
representation (bottom) of the region from exon 4 to exon 5 selected
for amplification experiments to detect spliced and unspliced RNA
transcripts using qRT-PCR. Specific primers designed are represented
by the two arrow pairs, which illustrate their approximate locations. b,
c qRT-PCR analysis showing relative mRNA levels of spliced and
unspliced TAZ RNA transcripts and splicing efficiency in U87MG-
and A172-sh-USP39-1 and -2 cells relative to controls. GAPDH was
used for normalization. d, e RNA protein immunoprecipitation was
performed using anti-USP39 (with IgG as control), and qRT-PCR
were used to detect the level of TAZ mRNA in the immunoprecipitated
complex. Student’s t-test: *p < 0.05, **p < 0.01
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Knockdown of USP39 was performed in U87MG and
A172 cells, and lysates were prepared from nuclear and
cytoplasmic fractions. In western blotting analysis, we
observed a strong decrease in the ratio of TAZ nuclear to
total protein levels in two cell populations with USP39
loss relative to controls (Fig. 6a, b). Immunofluorescence
staining was consistent with these findings (Fig. 6c).
Finally, transcriptional activity paralleled the loss of
nuclear TAZ; mRNA levels of TAZ target genes, BIRC5,
E2F1, and MYC were decreased (Fig. 6d) [22, 24, 36].
These data therefore indicated that USP39 was involved
in the transcriptional activation of TAZ.
Ectopic expression of USP39 and TAZ restores
malignant properties of glioma cells with the loss of
USP39 in vitro and in vivo
To further validate the putative oncogenic role of USP39 in
glioma and exclude off-target effects of the shRNAs,
USP39 was overexpressed in cells with depletion of USP39.
To investigate the functional role of TAZ protein in the
USP39-promoted pathway in glioma, U87MG-, and P3-sh-
USP39-1 cells were infected with a wild-type TAZ lenti-
viral expression construct. Efficiency of expression from
these constructs was assessed by western blotting; USP39
Fig. 6 Downregulation of USP39 decreases TAZ transcriptional
activity. a, b Western blotting analysis of total, cytoplasmic, and
nuclear fractions prepared from indicated cells. Bar graph showing the
ratio of TAZ nuclear protein (normalized to Histone H3) to total
protein (normalized to GAPDH) levels in modified and control (NC)
cells. c Representative images of immunofluorescence for TAZ (red) in
indicated cells. Nuclei are stained with DAPI (blue). Scale bars,
100 µm. d qRT-PCR analysis for expression of TAZ target genes in
U87MG- or A172-sh-USP39-1 compared with controls. GAPDH was
used for normalization. Student’s t-test: n.s.= not significant, *p <
0.05, **p < 0.01, ***p < 0.001
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or TAZ was increased in both U87MG- and P3-sh-USP39-1
cells (Fig. 7a).
Ectopic expression of USP39 or TAZ in U87MG- and
P3-sh-USP39-1 cells restored malignant properties. Cell
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proliferation reached levels observed in controls without the
loss of USP39 (Fig. 7b). In addition, luciferase activity,
from a Hippo pathway regulated luciferase reporter con-
struct, was rescued in U87MG-sh-USP39-1 cells as well as
transcription of genes downstream of TAZ (Fig. 7c, d).
These in vitro results were further validated in vivo through
orthotopic implantation of the various modified cell types.
Cell growth in U87MG- and P3-sh-USP39-1 cells with
USP39 or TAZ overexpression reached values similar to
those obtained from control cells (Fig. 7e, f). These data
overall demonstrated that TAZ was a critical downstream
effector mediating the oncogenic function of USP39 in
glioma.
Discussion
Previous studies have reported that USP39 contributes to
cancer progression and predicts poor prognosis in various
tumors [10–21]. For example, USP39 has been shown to be
essential for KRAS-driven cancer [35]. Here, analysis of
expression data from the Oncomine dataset demonstrated
that USP39 mRNA might be upregulated in GBM. We
found increased protein levels of USP39 to be associated
with higher tumor grade in an independent cohort of pri-
mary human gliomas. In functional experiments, we
demonstrated that this increase in USP39 promotes cell
proliferation, invasion, and migration in vitro and in vivo.
These results are consistent with an oncogenic role for
USP39 in the development of human glioma.
Based on a series of luciferase reporter assays designed
to probe activity in seven cancer-associated pathways, we
found that events downstream of Hippo signaling were
dramatically affected by USP39 levels in glioma. Previous
work from our lab supports a critical role for Hippo sig-
naling in the development of human glioma. We found that
actin like-6A (ACTL6A) promotes glioma progression by
directly associating with YAP/TAZ, which prevents ubi-
quitination of YAP/TAZ protein. We also observed that
ACTL6A mainly interacts with the C-terminal region of
YAP, thus inhibiting YAP from binding to the ubiquitin
ligase β-TrCP [37]. Other studies have also demonstrated a
critical role for YAP/TAZ in gliomagenesis [33, 34, 38].
Therefore, we aim to identify novel mechanisms of reg-
ulation for Hippo signaling in human gliomas.
We carefully investigated the relationship between
USP39 and Hippo signaling through protein analysis of
key components of the pathway. Protein levels of TAZ
were reduced with USP39 knockdown, but other key
components in the Hippo pathway, including LATS1/2
and YAP, remained unchanged. The existence of a
potential link between the protein expression of USP39
and TAZ was also supported by IHC performed on
sections from xenografts derived from modified U87MG
and P3 cells, as well as human primary glioma samples.
Although YAP and TAZ have been reported to act
synergistically to activate transcription [39], over-
expression of TAZ or knockdown of TAZ alone has been
found to substantially affect Hippo signaling (8 × GTIIC-
Luc reporter) [40]. We verified this result in glioma,
which explains why Hippo activity could be impaired
even in the presence of normal protein levels of YAP.
The decrease in Hippo signaling (~90%) also did not
parallel the reduction in TAZ protein levels (~50%) after
USP39 knockdown. TAZ is a transcriptional coactivator,
which cannot directly bind to DNA, but it interacts with
several oncogenic transcription factors, including
TEADs, to activate transcription. A study has reported
that TAZ mutants defective in interaction with TEADs
failed to accumulate in the nucleus [41]. So one plausible
interpretation would be that USP39 may also affect the
interaction between TAZ and transcription factors, which
might contribute to inhibition of Hippo signaling.
A fundamental question that remains is how USP39
drives the increase in TAZ protein. USP39 is reported to
be a splicing factor and to take part in the processing of
the mRNA of some genes [6–8, 35]. Although the reg-
ulation of TAZ expression has been thoroughly investi-
gated at the transcriptional level [42], the mechanisms
governing the processing of TAZ mRNA are less well
understood. We provide evidence that USP39 regulates
TAZ protein levels, at least in part, by controlling mRNA
maturation. According to the Ensembl database, there are
three primary transcripts that can be translated into full-
length TAZ protein. For detection of unspliced and
spliced TAZ mRNAs, we designed two primer pairs
specific for a region common to all three primary tran-
scripts. This method has been previously used to deter-
mine the splicing rate of various gene transcripts
[10, 43]. Indeed, a decrease in TAZ pre-mRNA splicing
efficiency was detected in cells with USP39 knockdown,
implicating a role for the protein in the maturation of
TAZ mRNA. Furthermore, USP39 plays a central role in
Fig. 7 Ectopic expression of USP39 and TAZ restores malignant
properties of glioma cells with knockdown of USP39 in vitro and
in vivo. a Western blotting analysis of lysates prepared from modified
U87MG and P3 cells. GAPDH was used for normalization. b OD from
CCK8 assays plotted as a function of time in hours for indicated cells
to evaluate cell viability. c Graphic representation of relative luciferase
activity from luciferase reporter constructs regulated by Hippo sig-
naling in U87MG cells from indicated groups. d qRT-PCR analysis of
the expression of TAZ target genes from indicated cells. GAPDH was
used for normalization. e, f Representative images of luciferase bio-
luminescence at the indicated days after injection of U87MG and P3
cells into the brains of nude mice. Graphic representation of the total
flux at the indicated days for the indicated cell types. Student’s t-test:
*p < 0.05, **p < 0.01, ***p < 0.001
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pre-mRNA splicing of many genes, including CAS-
P8AP2, CDCA8, MED19, SERPINB6, TAF9B, BORA,
KIF14, and ORC11 [35]. Combined with results from
previous studies [5, 9, 10], it is reasonable to speculate
that the effects of USP39 on the maturation of mRNA are
not merely specific to TAZ mRNA.
We also demonstrated that USP39 increases TAZ protein
level and thus enhances its nuclear function. However, the
mechanism linking USP39 to TAZ activation is unclear.
TAZ has been identified as an integral component of the
β-catenin destruction complex, which effectively sequesters
TAZ in the cytoplasm, and knockdown of USP39 has also
been shown to lead to decreased protein expression of
β-catenin [44–46]. USP39 silencing might therefore
enhance the β-catenin destruction complex, and thus lead to
cytoplasmic retention and reduced nuclear localization of
TAZ. Further investigation is necessary to illuminate the
specific mechanism.
In summary, our work indicated that upregulated
expression of USP39 is a common event in human
gliomas, and that it promotes malignant tumor properties
in gliomas both in vitro and in vivo. Thus, USP39
appears to have oncogenic properties in the development
of human gliomas. Our study further demonstrated that
the oncogenic activity of USP39 is due to its ability to
activate TAZ. However, this activity is independent of
canonical Hippo signaling, and is instead due to its
ability to enhance pre-mRNA splicing of TAZ. Finally,
our work provides an important basis for the develop-
ment of diagnostic and therapeutic approaches in the
treatment of glioma patients using USP39.
Materials and methods
Cell lines and cell culture
Human glioma cell lines LN18, U87MG, A172, and U251
were obtained from the Culture Collection of the Chinese
Academy of Sciences (Shanghai, China). NHA and primary
GBM#P3 cells were kindly provided by Professor Rolf
Bjerkvig (University of Bergen; Bergen, Norway). P3 cells
were cultured in Dulbecco’s modified Eagles’s medium
(DMEM)/F-12 medium (Thermo Fisher Scientific; Wal-
tham, MA, USA) supplemented with 2% B27 Neuro Mix
(Thermo Fisher Scientific), 20 ng/mL epidermal growth
factor (EGF; Thermo Fisher Scientific), and 10 ng/mL basic
fibroblast growth factor (βFGF; PeproTech; Rocky Hill, NJ,
USA). All other cells were cultured in DMEM (Thermo
Fisher Scientific) supplemented with 10% fetal bovine
serum (FBS; Thermo Fisher Scientific). Cells were main-
tained at 37 °C in a humidified chamber containing 5% CO2.
Lentiviral transductions
U87MG, A172, or P3 cells were infected with lentivirus
containing two different shRNAs targeting USP39 (sh-
USP39-1, sh-USP39-2; OBiO Technology, Shanghai,
China). After 48 h, cells were cultured in DMEM or DMEM/
F-12 containing puromycin (2 μg/mL; Thermo Fisher Sci-
entfic) for an additional 2 weeks to select for cells containing
the constructs. For ectopic expression of USP39 or TAZ,
U87MG- and P3-sh-USP39-1 cells were infected with len-
tiviral constructs expressing full-length USP39 or TAZ
(OBiO Technology). The sequences of the shRNAs and
siRNAs used are the following: sh-negative control, 5′-UU
CUCCGAACGUGUCACGUTT-3′; sh-USP39-1, 5′-GCAU
AUGAUGGUACCACUUTT-3′; sh-USP39-2, 5′-CCUUCA





Nuclear and cytoplasmic fractions from different cell
populations were isolated using Nuclear and Cytoplasmic
Extraction Reagents (Thermo Fisher Scientific), according
to the manufacturer’s instructions. GAPDH and Histone H3
were used for normalization.
Immunohistochemistry
Glioma samples were obtained from 46 patients (WHO
II–IV) who had undergone surgeries performed at the
Department of Neurosurgery at the Qilu Hospital. Non-
neoplastic brain tissue samples were collected from six
patients who underwent partial resection due to trauma or
other conditions unrelated to cancer. Tissues were fixed
with 4% formalin, embedded in paraffin, and sectioned
(4 µm). IHC assays were performed using the SPlink
Detection Kit and DAB (ZSGB-BIO; Beijing, China)
according to the manufacturer’s instructions. The following
primary antibodies were used: USP39 (#ab131332, 1:200,
Abcam, Cambridge, MA, USA), TAZ (#ab84927, 1:200,
Abcam), and Ki67 (#ab92742, 1:800, Abcam).
USP39 staining was scored as follows: 0, no staining; 1,
weak staining in <50% cells; 2, weak staining in ≥50%
cells; 3, strong staining in <50% cells; and 4, strong staining
in ≥50% cells.
Immunofluorescence
Cells were cultured in 24-well plates, fixed with 4% par-
aformaldehyde, permeabilized with 0.4%Triton X-100,
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blocked with 5% bovine serum albumin, and incubated with
primary antibody against TAZ (#8418, 1:200, Cell Signal-
ing Technology, Beverly, MA, USA) at 4 °C overnight.
Primary antibody was detected with an Alexa Fluor 594
conjugated goat anti-rabbit IgG antibody (#ab150080,
1:800; Abcam), and cell nuclei were stained with DAPI
(Sigma-Aldrich; St. Louis, MO, USA). Images were
obtained under fluorescence microscopy (Leica; Wetzlar,
Germany).
Western blotting analysis
Cells and tissues were lysed in RIPA Lysis and Extraction
Buffer (Thermo Fisher Scientific) containing a protease
inhibitor cocktail (Sigma-Aldrich). Protein lysates (20 μg)
were run on SDS-PAGE and transferred onto poly-
vinylidene difluoride membranes. Membranes were blocked
in 5% skim milk, and incubated overnight with primary
antibodies at 4 °C followed by incubation with secondary
antibodies (ZSGB-BIO). Proteins on membranes were
visualized using the Chemiluminescent Reagents Kit (Mil-
lipore; Billerica, MA, USA). Signals were detected with the
Chemi-Doc XRS+ (Bio-Rad; Hercules, CA, USA) and
quantified using Image Lab 3.0 software (Bio-Rad). The
following primary antibodies were used for western blot-
ting: USP39 (#ab131332, Abcam), Histone H3(#ab176842,
Abcam), Ki67 (#ab92742, Abcam), GAPDH (#sc-25778,
Santa Cruz Biotechnology; Dallas, TX, USA), LATS1
(#3477, Cell Signaling Technology), LATS2(#5888, Cell
Signaling Technology), YAP (#14074, Cell Signaling
Technology), and TAZ (#8418, Cell Signaling
Technology).
Cell invasion and migration assay
Cells (2 × 104/well) were seeded into the upper chamber of
transwell permable supports (pore size: 8 μm; Corning
Costar; Tewksbury, MA, USA), and medium containing
30% FBS (600 μL) was added into the lower chamber. For
invasion assays, the upper chamber was coated with
Matrigel (BD Biosciences; Bedford, MA, USA). Chambers
were incubated at 37 °C for 24–36 h, and cells were fixed
with 4% paraformaldehyde and stained with crystal violet
(Solarbio; Beijing, China). Images were obtained from five
random fields (×100) in each well. All experiments were
performed in triplicate.
Cell viability assay
Cells (5 × 103/well) were seeded into 96-well plates and
incubated overnight. CCK8 solution (Dojindo; Kumamoto,
Japan) was added to evaluate cell viability every 24 h
according to the manufacturer’s instructions. Samples were
measured at 450 nm in a microplate reader (PerkinElmer;
San Jose, CA, USA).
EdU assay
Cells (2 × 104/well) were seeded into 24-well plates and
incubated overnight. Proliferation was evaluated using the
EdU Kit (Rib-bio; Guangzhou, China) according to the
manufacturer’s instructions. Images were obtained from
three random fields (×200) under fluorescence microscopy
(Leica).
Colony forming assay
U87MG and A172 cells (1 × 103/well) were seeded into 6-
well plates, and P3 cells were seeded into 6-well plates
coated with poly-l-lysine (Solarbio). After 2 weeks, cells
were fixed with 4% paraformaldehyde and stained with
crystal violet (Solarbio). The total number of colonies was
counted per well. All experiments were performed in
triplicate.
Reverse transcription PCR
Cell and tissue RNA isolation were carried out using TRIzol
Reagent (Takara; Tokyo, Japan) according to manu-
facturer’s instructions. Isolated total RNA was quantified
and used to generate cDNA using a reverse transcription kit
(Toyobo; Osaka, Japan). mRNA levels were quantified by
real-time PCR. GAPDH served as an internal control. The
following primers were used:
GAPDH, forward, 5′-GCACCGTCAAGGCTGAGAAC-




ACTTTCTCCGCAGTTTC-3′; E2F1, forward, 5′-GCCAT
CCAGGAAAAGGTGTGA-3′, reverse, 5′-GTGATGTCA-
GATGCGCCG-3′; MYC, forward, 5′-GGTAGTGGAAA
ACCAGCAGCC-3′, reverse, 5′-TTCTCCTCCTCGTCGC
AGTA-3′; TAZ unspliced mRNA, forward, 5′-GGC
TGCAATACCGTGTTACC-3′, reverse, 5′-CAAAGTCAC
CCAAAGCGTGT-3′; TAZ spliced mRNA, forward, 5′-CC
CAGCCAAATCTCGTGATGAA-3′, reverse, 5′-AGCGC




Cells were seeded in 96-well plates (3 × 103/well). After
24 h, luciferase reporter constructs containing a tran-
scription factor responsive element upstream of firefly
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luciferase were co-transfected with a Renilla luciferase
construct into cells using Lipofectamine 3000 (Thermo
Fisher Scientific), according to the manufacturer’s
instructions. After 24 h, luciferase activity was analyzed
using the Dual Luciferase Reporter Assay kit (Promega)
according to the manufacturer’s protocol. Renilla activity
was used to normalize luciferase reporter activity.
Experiments were performed in triplicate. Plasmids used
were the following: firefly luciferase driven by Elk-1/SRF,
AP-1, NFκB, RBP-Jκ, SMAD2/SMAD3/SMAD4, or
TCF/LEF (Qiagen; Hilden, Germany) was co-transfected
with Constitutively expressing Renilla luciferase con-
struct (Qiagen); YAP/TAZ-responsive luciferase reporter
construct, 8 × GTIIC-Luc (Addgene; Cambridge, MA,
USA) was co-transfected with pGL4-SV40 driven Renilla
luciferase (Promega; Madison, WI, USA).
RNA-binding protein immunoprecipitation assay
RIP analysis was performed using the Magna RIP RNA-
binding protein immunoprecipitation kit (Millipore, Bill-
erica, MA, USA) and the USP39 antibody (#ab131332,
Abcam) following the manufacturer’s protocol. Co-
precipitated RNAs were isolated, purified, and subjected
to qRT-PCR analysis.
Animal studies
Athymic BALB/c nude mice (male, 3- to 4-week-old;
GemPharmatech Co., Ltd; Nanjing, China) were randomly
divided into indicated groups. Luciferase-expressing cells
(1 × 106) were inoculated into the frontal lobe using a ste-
reotactic apparatus (KDS310, KD Scientific; Holliston,
MA, USA). Bioluminescence images were captured using
an imaging system (PerkinElmer) every 5 days. When
animals were displaying symptoms, such as apathy,
decreased activity, severe hunchback posture, dragging
legs, unkempt fur, or loss of body weight, they were killed
by cervical dislocation. If necessary, animals were perfused
with saline solution and 4% paraformaldehyde, and excised
brains were prepared for further examination by HE and
IHC staining.
Statistical analysis
All experiments were carried out with at least three repli-
cates. Data were expressed as the mean ± SEM, and statis-
tical significance was calculated with unpaired two-tailed,
Student’s t-tests, unless otherwise stated. Survival curves
were estimated by the Kaplan–Meier method and compared
using the log-rank test. A two-sided χ2-test and Fisher’s
exact test were both used to determine the association
between USP39 and TAZ. A two-sided χ2-test was used to
determine the association between USP39 expression and
clinicopathological factors. GraphPad Prism version
7.00 software program (GraphPad; La Jolla, CA, USA) was
used to analyze data from in vitro and in vivo experiments.
Differences were considered as statistically significant when
p < 0.05.
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